61 results on '"Baraldi, Anna"'
Search Results
2. Neutralizing the Tentacles of Organized Crime. Assessment of the Impact of an Anti-Crime Measure on Mafia Violence in Italy
3. Ballot structure and political selection. Evidence from changes in electoral rules
4. Does corruption hinder female political participation? Evidence from a measure against organized crime
5. Eppur si muove: an evaluation of museum policy reform in Italy
6. Neutralizing the Tentacles of Organized Crime. Assessment of an Anti-Crime Measure in Fighting Mafia Violence
7. Mafia wears out women in power: Evidence from italian municipalities
8. Self-selecting candidates or compelling voters: How organized crime affects political selection
9. Political Competition
10. SURVIVAL OF MYELOMA PATIENTS RECEIVING BISPHOSPHONATES IN A "REAL LIFE" EXPERIENCE: POTENTIAL IMPACT ON RISK OF OSTEONECROSIS OF THE JAW (ONJ)
11. PREVENTION AND SCREENING OF OSTEONECROSIS OF JAW (ONJ) IN MYELOMA PATIENTS : A MONOISTITUTIONAL FIFTEEN-YEAR EXPERIENCE
12. Public investment and growth: Lessons learned from 60-years experience in Southern Italy
13. Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial
14. Do Voters Choose Better Politicians than Political Parties? Evidence from a Natural Experiment in Italy
15. Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
16. The Effect of Fiscal Decentralization on Corruption: A Non-linear Hypothesis
17. Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
18. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients
19. Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study
20. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
21. Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology
22. Growth Accounting e spesa per investimenti della Cassa per il Mezzogiorno nelle regioni meridionali, 1951-1996
23. Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials
24. "Osteonecrosis of Jaw (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma (MM) : Monocentric Experience of Decreasing ONJ Incidence after Preventive Measures."
25. Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures
26. Democracy, Political Competition and Economic Growth
27. Effect of the proportionality degree of electoral systems on corruption
28. Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
29. The role of political competition in the link between electoral systems and corruption: an extension
30. Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon
31. Proportionality Degree of Electoral Systems and Growth: A Panel Data Test
32. Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib
33. Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM
34. The role of political competition in the link between electoral systems and corruption: The Italian case
35. Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients
36. Monoclonal Gammopathy After Allogeneic Hematopoietic Stem Cell Transplant As a Marker For GvHD Onset
37. Reverse causality in the R&D–patents relationship: an interpretation of the innovation persistence
38. Epstein–Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation
39. Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
40. The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair
41. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
42. Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)
43. Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study
44. A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.
45. Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
46. Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.
47. The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.
48. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
49. Jaw Osteonecrosis Associated with Intravenous Bisphosphonate: Is Incidence Reduced After Adoption of Dental Preventive Measures?
50. IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution: Proposal and Validation of a Prognostic Scoring System
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.